Jeffrey J Swigris

Summary

Affiliation: National Jewish Medical and Research Center
Country: USA

Publications

  1. doi request reprint Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO, USA Electronic address
    Respir Med 108:181-8. 2014
  2. pmc St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO 80206, USA
    Chest 143:1671-8. 2013
  3. pmc The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
    Respir Med 106:1447-55. 2012
  4. pmc Patient-reported outcomes in idiopathic pulmonary fibrosis research
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson St, Denver, CO 80206, USA
    Chest 142:291-7. 2012
  5. pmc Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO 80206, USA
    Respir Med 106:588-93. 2012
  6. pmc Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease
    Jeffrey J Swigris
    National Jewish Health, Denver, CO 80206, USA
    Respir Med 104:1350-5. 2010
  7. pmc The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Interstitial Lung Disease Program, National Jewish Health, Denver, Colorado 80206, USA
    BioDrugs 24:49-54. 2010
  8. pmc Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, Colorado 80206, USA
    Respir Care 56:783-9. 2011
  9. pmc Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Southside Building, Office No G011, 1400 Jackson St, Denver, CO 80206, USA
    Chest 140:1261-6. 2011
  10. pmc Development of the ATAQ-IPF: a tool to assess quality of life in IPF
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson Street, Denver, Colorado 80206, USA
    Health Qual Life Outcomes 8:77. 2010

Detail Information

Publications43

  1. doi request reprint Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO, USA Electronic address
    Respir Med 108:181-8. 2014
    ..Dyspnea is a hallmark symptom of idiopathic pulmonary fibrosis (IPF), and dyspnea induced physical activity limitation is a prominent driver of quality of life impairment among IPF patients...
  2. pmc St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO 80206, USA
    Chest 143:1671-8. 2013
    ..Whether St. George's Respiratory Questionnaire (SGRQ), a respiratory-specific HRQL instrument, captures longitudinal changes in HRQL in patients with LAM is unknown...
  3. pmc The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
    Respir Med 106:1447-55. 2012
    ..Our goal in this study was to examine whether the UCSD Shortness of Breath Questionnaire does so in patients with IPF...
  4. pmc Patient-reported outcomes in idiopathic pulmonary fibrosis research
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson St, Denver, CO 80206, USA
    Chest 142:291-7. 2012
    ....
  5. pmc Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO 80206, USA
    Respir Med 106:588-93. 2012
    ..In studies of idiopathic pulmonary fibrosis (IPF), whites makeup the vast majority of subjects. Whether ethnic/racial differences in idiopathic pulmonary fibrosis occur in the general population is unknown...
  6. pmc Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease
    Jeffrey J Swigris
    National Jewish Health, Denver, CO 80206, USA
    Respir Med 104:1350-5. 2010
    ..Dyspnea is the cardinal symptom in patients with any type of interstitial lung disease (ILD); however, there are limited data on dyspnea among patients with connective tissue disease-related ILD (i.e., CTD-ILD)...
  7. pmc The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Interstitial Lung Disease Program, National Jewish Health, Denver, Colorado 80206, USA
    BioDrugs 24:49-54. 2010
    ..Initial results from a trial examining the efficacy of a dual endothelin receptor antagonist suggest that this approach may delay disease progression in a subset of patients with IPF...
  8. pmc Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, Colorado 80206, USA
    Respir Care 56:783-9. 2011
    ..Information on the benefits of pulmonary rehabilitation (PR) in patients with idiopathic pulmonary fibrosis (IPF) is growing, but PR's effects on certain important outcomes is lacking...
  9. pmc Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Southside Building, Office No G011, 1400 Jackson St, Denver, CO 80206, USA
    Chest 140:1261-6. 2011
    ..A recently published report from the United Kingdom suggested an association between sarcoidosis and pulmonary embolism (PE). We sought to examine whether this association was present among US decedents with sarcoidosis...
  10. pmc Development of the ATAQ-IPF: a tool to assess quality of life in IPF
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson Street, Denver, Colorado 80206, USA
    Health Qual Life Outcomes 8:77. 2010
    ..There is no disease-specific instrument to assess health-related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF)...
  11. pmc The SF-36 and SGRQ: validity and first look at minimum important differences in IPF
    Jeffrey J Swigris
    Interstitial Lung Disease Program in the Autoimmune Lung Center and Division of Psychosocial Medicine, National Jewish Health, Denver, CO, USA
    Respir Med 104:296-304. 2010
    ..Health-related quality of life (HRQL) is an important outcome in drug trials. Little is known about how the Short Form-36 (SF-36) and Saint George's Respiratory Questionnaire (SGRQ) perform in idiopathic pulmonary fibrosis (IPF)...
  12. pmc Sarcoidosis-related mortality in the United States from 1988 to 2007
    Jeffrey J Swigris
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO 80206, USA
    Am J Respir Crit Care Med 183:1524-30. 2011
    ..Objectives: To examine mortality rates and underlying causes of death among United States decedents with sarcoidosis from 1988-2007...
  13. pmc Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Interstitial Lung Disease Program and Autoimmune Lung Center, National Jewish Medical and Research Center, Denver, CO 80206, USA
    Chest 136:841-8. 2009
    ....
  14. pmc Exercise peripheral oxygen saturation (SpO2) accurately reflects arterial oxygen saturation (SaO2) and predicts mortality in systemic sclerosis
    J J Swigris
    Interstitial Lung Disease Program and Autoimmune Lung Center, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
    Thorax 64:626-30. 2009
    ..Measures of oxygenation have not been assessed for prognostic significance in systemic sclerosis-related interstitial lung disease (SSc-ILD)...
  15. pmc Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation
    Jeffrey J Swigris
    Autoimmune Lung Center, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
    Respir Med 102:1675-80. 2008
    ..Pulmonary rehabilitation helps to accomplish many of these goals in patients with chronic obstructive pulmonary disease, and emerging data suggest that it may do the same for patients with IPF...
  16. pmc Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives
    Jeffrey J Swigris
    Division of Pulmonary Medicine, National Jewish Medical and Research Center, Denver, CO, USA
    Health Qual Life Outcomes 3:61. 2005
    ..On a broader scale, to provide the best care for people with IPF, clinicians must appreciate--from patients' perspectives--how this disease affects various aspects of their lives...
  17. ncbi request reprint Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease
    Jeffrey J Swigris
    Autoimmune Kung Center, Interstitial Lung Disease Program, National Jewish Medical and Research Center, 1400 Jackson St, Molly Blank J229, Denver, CO 80206, USA
    Chest 130:30-6. 2006
    ..In this study, our objectives were to examine the safety and tolerability of mycophenolate mofetil (MMF) and to determine its impact on lung function in patients with CTD-ILD...
  18. ncbi request reprint Evaluation of bosentan for idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Assistant Professor of Medicine, Interstitial Lung Disease Program, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO, USA
    Expert Rev Respir Med 2:315-21. 2008
    ..Results from this trial are anticipated in 2009...
  19. doi request reprint Pulmonary and thrombotic manifestations of systemic lupus erythematosus
    Jeffrey J Swigris
    Autoimmune Lung Disease Center, National Jewish Medical and Research Center, Denver, CO 80206, USA
    Chest 133:271-80. 2008
    ..This article offers the reader a comprehensive review of the numerous pulmonary and thrombotic manifestations of SLE and suggests approaches to their management...
  20. pmc Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Interstitial Lung Disease Program and Autoimmune Lung Center, National Jewish Health, Denver, Colorado 80206, USA
    Respirology 16:439-45. 2011
    ..In patients with IPF, we sought to validate that abnormal heart rate recovery at 1 min (HRR1) after six-minute walk test (6MWT) predicts mortality and to explore the relationship between abnormal HRR1 and pulmonary hypertension (PH)...
  21. pmc FEV1 over time in patients with connective tissue disease-related bronchiolitis
    Evans R Fernandez Perez
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO 80206, USA
    Respir Med 107:883-9. 2013
    ..Fibrosis or inflammation of the bronchioles is a well-known manifestation of connective tissue disease (CTD). However, the natural history of CTD-related bronchiolitis is largely unknown...
  22. pmc Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease
    Aryeh Fischer
    Autoimmune and Interstitial Lung Disease Program, National Jewish Health, Denver, Colorado 80206, USA
    J Rheumatol 40:640-6. 2013
    ..We examined the tolerability and longitudinal changes in pulmonary physiology in a large and diverse cohort of patients with CTD-ILD treated with MMF...
  23. pmc Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease
    Aryeh Fischer
    Autoimmune and Interstitial Lung Disease Program, Department of Medicine, National Jewish Health, 1400 Jackson St, Denver, CO 80206, USA
    Chest 136:1072-8. 2009
    ..To describe a cohort of patients who presented with interstitial lung disease (ILD) of unknown cause, features of primary Sjögren syndrome (pSS), and a positive minor salivary gland biopsy (MSGB)...
  24. doi request reprint Rheumatoid arthritis-interstitial lung disease-associated mortality
    Amy L Olson
    Division of Pulmonary and Critical Care Medicine, Interstitial Lung Disease Program, and Autoimmune Lung Center, National Jewish Health, Denver, Colorado, USA
    Am J Respir Crit Care Med 183:372-8. 2011
    ..Mortality rates from rheumatoid arthritis-associated interstitial lung disease (RA-ILD) are largely unknown...
  25. ncbi request reprint Pericardial abnormalities predict the presence of echocardiographically defined pulmonary arterial hypertension in systemic sclerosis-related interstitial lung disease
    Aryeh Fischer
    Division of Rheumatology, National Jewish Medical and Research Center, 1400 Jackson St, Denver, CO 80206
    Chest 131:988-92. 2007
    ..To determine the prevalence and significance of pericardial abnormalities in systemic sclerosis (SSc)-related interstitial lung disease (ILD)...
  26. pmc Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia
    Aryeh Fischer
    National Jewish Health, Interstitial and Autoimmune Lung Disease Program, Denver, CO 80206, United States
    Respir Med 103:1719-24. 2009
    ..To describe the clinical features of patients presenting with "idiopathic" interstitial pneumonia that were diagnosed with anti-synthetase syndrome based on clinical features and positive anti-PL-7 or PL-12 antibodies...
  27. pmc Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease
    Aryeh Fischer
    Autoimmune Lung Center, National Jewish Health, Denver, CO 80206, USA
    Respir Med 106:1040-7. 2012
    ..We sought to characterize a novel cohort of patients with lung disease, anti-cyclic citrullinated peptide (CCP) antibody positivity, without rheumatoid arthritis (RA) or other connective tissue disease (CTD)...
  28. doi request reprint Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival
    Aryeh Fischer
    Autoimmune Lung Disease Center, Department of Medicine, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
    Chest 134:601-5. 2008
    ..To evaluate the pathologic patterns, clinical features, and survival among subjects with scleroderma (ie, systemic sclerosis [SSc]) and clinically significant interstitial lung disease (ILD) evaluated at an ILD center...
  29. pmc The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference
    Jeffrey J Swigris
    Interstitial Lung Disease Program and Autoimmune Lung Center, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
    Thorax 65:173-7. 2010
    ....
  30. pmc Obstructive sleep apnea does not promote esophageal reflux in fibrosing interstitial lung disease
    Manju Pillai
    Sleep Medicine Program, National Jewish Health, Denver, CO, USA
    Respir Med 106:1033-9. 2012
    ..We conducted this study to test our hypothesis that, in patients with fILD, OSA would exacerbate diaphragm/LES dysfunction and increase the propensity for-and severity of - GER...
  31. doi request reprint Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
    Joshua J Solomon
    Autoimmune Lung Center and ILD Program, National Jewish Health, Denver, CO 80206, USA
    Respir Med 107:1247-52. 2013
    ..Controversy exists as to the prognostic significance of these patterns among patients with RA-ILD...
  32. pmc Connective tissue disease-associated interstitial lung disease: a call for clarification
    Aryeh Fischer
    Division of Rheumatology, National Jewish Health and University of Colorado, Denver, CO 80206, USA
    Chest 138:251-6. 2010
    ....
  33. pmc Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter
    Amy L Olson
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Chest 136:16-22. 2009
    ..Our objective was to determine if mortality rates from IPF and/or PF of any cause exhibit seasonal variation...
  34. doi request reprint Idiopathic pulmonary fibrosis: diagnosis and epidemiology
    Amy L Olson
    Interstitial Lung Disease Program, Division of Pulmonary and Critical Care Medicine, Autoimmune Lung Center, National Jewish Health, Denver, CO 80206, USA
    Clin Chest Med 33:41-50. 2012
    ..This article summarizes the approach to diagnosing IPF and reviews epidemiologic data on IPF...
  35. pmc Myositis-related interstitial lung disease and antisynthetase syndrome
    Joshua Solomon
    Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
    J Bras Pneumol 37:100-9. 2011
    ..Among patients with antisynthetase syndrome-related ILD, the response to immunosuppressive medications is generally, but not universally, favorable...
  36. ncbi request reprint Acute interstitial pneumonia and acute exacerbations of idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Pulmonary and Critical Care Medicine Division, National Jewish Medical and Research Center, Denver, Colorado 80203, USA
    Semin Respir Crit Care Med 27:659-67. 2006
    ..Survivors of the acute event can recover to their previous baseline; however, most AIP survivors will stabilize with some functional impairment, whereas in those with AEIPF, progressive fibrosis with functional deterioration is the rule...
  37. doi request reprint Health-related quality of life in idiopathic pulmonary fibrosis: where are we now?
    Amanda Belkin
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO 80206, USA
    Curr Opin Pulm Med 19:474-9. 2013
    ....
  38. ncbi request reprint Idiopathic pulmonary fibrosis: a decade of progress
    Jeffrey J Swigris
    Interstitial Lung Disease Program, National Jewish Medical and Research Center, Denver, Colorado 80206, USA
    J Bras Pneumol 32:249-60. 2006
    ..This article offers the reader a view of the recent advances in idiopathic pulmonary fibrosis research, with a focus on natural history, pathogenesis and treatment...
  39. doi request reprint Patient expectations and experiences in idiopathic pulmonary fibrosis: implications of patient surveys for improved care
    Amanda Belkin
    Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, CO, USA
    Expert Rev Respir Med 8:173-8. 2014
    ..Patients treated in centers of excellence expressed greater satisfaction with quality of care and treatments, and also valued the opportunity to interact with other IPF patients. ..
  40. ncbi request reprint Health-related quality of life among patients with idiopathic pulmonary fibrosis
    Jeffrey J Swigris
    Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA 94305 5236, USA
    Chest 127:284-94. 2005
    ....
  41. ncbi request reprint Idiopathic pulmonary fibrosis: challenges and opportunities for the clinician and investigator
    Jeffrey J Swigris
    Division of Pulmonary and Critical Care Medicine, Stanford University, Medical Center, Stanford, CA 94305 5236, USA
    Chest 127:275-83. 2005
    ....
  42. ncbi request reprint Lymphoid interstitial pneumonia: a narrative review
    Jeffrey J Swigris
    Division of Pulmonary and Critical Care Medicine, Stanford University, 300 Pasteur Drive, Stanford, CA 94305 5236, USA
    Chest 122:2150-64. 2002
    ..Approximately 33 to 50% of patients die within 5 years of diagnosis, and approximately 5% of cases of LIP transform to lymphoma...
  43. ncbi request reprint Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003
    Amy L Olson
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver Colorado 80262, USA
    Am J Respir Crit Care Med 176:277-84. 2007
    ..From the late 1970s to the early 1990s, studies found that mortality rates for pulmonary fibrosis were increasing. Recent data for mortality from pulmonary fibrosis are unavailable...